✦ LIBER ✦

Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?

✍ Scribed by R. Itzykson; S. Thépot; O. Beyne-Rauzy; S. Ame; F. Isnard; F. Dreyfus; C. Salanoubat; A.L. Taksin; Y. Chelgoum; C. Berthon; J.V. Malfuson; L. Legros; N. Vey; P. Turlure; C. Gardin; S. Boehrer; L. Ades; P. Fenaux

Book ID: 113773620
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 204 KB
Volume: 36
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2011.11.019

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Predicting the outcome of patients with

Predicting the outcome of patients with higher-risk myelodysplastic syndrome treated with hypomethylating agents

✍ Itzykson, Raphael; Fenaux, Pierre 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 228 KB

Lenalidomide in lower-risk myelodysplast

Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents

✍ David Sibon; Giovanna Cannas; Fiorenza Baracco; Thomas Prebet; Norbert Vey; Anne 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 140 KB

510 Addition of All-Trans Retinoic Acid

510 Addition of All-Trans Retinoic Acid (ATRA) to the Combination of Fludarabine, Cytarabine, Idarubicin, With or Without GCSF in Older, Higher Risk Patients with AML and High-Risk MDS Does Not Improve the Outcome in Those with NPM1 Mutation

✍ Asifa Malik; Carlos Bueso-Ramos; Stefan Faderl; Eli Estey; Susan O'Brien; Michae 📂 Article 📅 2011 🏛 Elsevier 🌐 English ⚖ 153 KB